Novel PP2A-Activating Compounds in Neuroblastoma
PP2A activators decreased NB cell viability, proliferation, and motility. In vivo experiments show that PP2A activators have more significant effects on tumorigenesis in <i>MYCN-amplified</i> tumors. Finally, phosphorylation of MYCN protein was decreased following treatment with novel sulfonamide PP2A activators. These data and mechanistic insights may be useful for developing new PP2A-based therapies that target MYCN for the treatment of NB.
Authors
- Laura V. Bownes
- Michael H. J. Ohlmeyer (ORCID: https://orcid.org/0000-0003-1412-543X)
- Hooper R. Markert (ORCID: https://orcid.org/0000-0001-9698-5614)
- Raoud Marayati (ORCID: https://orcid.org/0000-0002-2848-3927)
- Jamie M. Aye (ORCID: https://orcid.org/0000-0001-8440-1263)
- Elizabeth Ann Beierle (ORCID: https://orcid.org/0000-0002-4613-0527)
- Karina J. Yoon (ORCID: https://orcid.org/0000-0002-0830-571X)
- Michael H. Erwin (ORCID: https://orcid.org/0000-0002-6633-4981)
- Janet R. Julson (ORCID: https://orcid.org/0000-0001-8213-443X)
- Colin H. Quinn (ORCID: https://orcid.org/0000-0001-7853-3948)
- Nazia Nazam (ORCID: https://orcid.org/0000-0003-0517-6841)
- Jerry E. Stewart (ORCID: https://orcid.org/0000-0003-4108-5381)
- Sarah Shirley
Institutions
- University of Alabama at Birmingham (US)
- Princeton Satellite Systems (United States) (US)
Publication Details
- Journal
- Cancers
- Published
- 2024-11-15
- DOI
- https://doi.org/10.3390/cancers16223836
- Citations
- 4
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.48